Provided herein are compositions and methods to that target microbial proteases to ameliorate the intestinal barrier dysfunction and restore mucosal integrity. They are useful to treat and prevent diseases and disorders caused by pathogenic bacteria in the gastrointestinal system of a subject.

Provided herein are methods for detecting a Ewing sarcoma breakpoint region 1 (EWSR1) fusion gene encoding a neoantigen (e.g., in a patient sample), as well as methods of prognosis and treatment related thereto, in some embodiments, the methods further comprise administering a cancer immunotherapy. In some embodiments, the EWSR1 fusion gene is a fusion gene between EWSR1 and WT1, Fill, ERG, FEV, NR4A3, ATF1, CREB1, CREM, CREB3L/CREB3L2, PA7Z1, NFATC2, KLFI5, C11orf93, ZNF444, PBX1, DDIT3, or TFCP2 that encodes a neoantigen.

Described herein are compositions that comprise one or more Babesia microti antigens, one or more Babesia microti nucleic acid molecules, or one or more anti-Babesia microti antibodies and uses thereof in methods for the prophylaxis of babesiosis, the treatment of babesiosis and the monitoring of individuals undergoing prophylactic or therapeutic administration of the compositions of the invention.

A system and method for alerting a healthcare provider to ineffective prescribed medications is provided. A laboratory system receives test results with genetic markers for a patient, queries a database containing medications known to be ineffective in persons having particular genetic markers to determine whether any medications prescribed by, or likely to be prescribed by, a healthcare provider to the patient are known to be ineffective in persons having the same genetic markers as the patient, and transmits an alert containing such information to a healthcare provider system for the healthcare provider.

The present invention relates to methods of diagnosing an inflammatory disorder in a patient, as well as methods of monitoring the progression of an inflammatory disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.

Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension. We have identified CCL21 as anti-remodelling efficacy biomarker for pulmonary hypertension. CCL21 was found to be highly sensitive and specific in discriminating pulmonary hypertension patients from matched controls. CCL21 was upregulated in pulmonary hypertension and down-regulated with treatment with an anti-remodelling agent.

##STR00001##

The invention relates a fluorescent compound of formula I: wherein A is selected from P, P═O and N; .Math.R.sup.1 is a residue comprising an oxygen atom.Math.R.sup.2 is a residue comprising an oxygen atom, or a halogen, .Math.R.sup.3, R.sup.4 and R.sup.5 are alkyls, possibly substituted or a salt or a solvate thereof. The compound is useful as a fluorescent probe sensitive to membrane fluidity and for diagnosing cancer.

The invention relates to the field of diagnostic immunology. Provided are means and methods for multiparameter cytometry-based leukocyte subsetting, which is advantageously used for the monitoring of the immune status of a subject, and/or for monitoring the effects of an immune modulatory treatment. Provided among others is a reagent composition comprising antibodies conjugated to a detectable label, the conjugated antibodies being directed against the following combination of markers: CD141, HLA-DR, CD16, CD33, CD300e, CD303 and CD14, wherein the antibodies directed against CD300e and CD303 may be conjugated to the same label.

Method of Detecting or Monitoring Minimal Residual Disease The application describes a method of identifying minimal residual disease (MRD) in a monoclonal gammopathy patient, comprising detecting the presence or absence of a monoclonal free light chain (FLC) in a sample from the patient by mass spectrometry (MS).

Methods of treating cancer with a combination of a WEE1 inhibitor and a DNA-damaging agent in patients having SLFN11-deficient cancer cells are disclosed herein.